OxThera get funding for orphan project

OxThera AB, a privately-held Stockholm-based biotechnology company, has raised SEK 70 million (€7.5 million) to finance clinical development of Oxabact, a treatment for primary hyperoxaluria (PH), a genetic disorder that can lead to kidney failure.